On 3 April 2018, Brian Anthony Whittle FRPharmS, aged 85 years, of Loughton, Milton Keynes. Dr Whittle registered with the Society in 1955 and left in 2017.
In 1954 Whittle graduated with a BPharm from the University of Nottingham. In 1957 he received an MSc from the University of London, and in 1964 he graduated with a PhD in pharmacology from the same institution.
Between 1960 and 1969, Whittle was head of the Central Nervous Systems Unit at ICI Pharmaceuticals Limited. He then spent 10 years as head of pharmacology at Reckitt and Colman PLC. Between 1979 and 1981, Whittle was director of regulatory affairs and health registration at Wyeth Europa. In 1981, he formed Brian Whittle Associates, a pharmaceutical development consultancy firm. He also established a community pharmacy in Hornsea, East Yorkshire
In 1990 Whittle and Geoffrey Guy co-founded Phytopharm, a pharmaceutical company that specialised in natural products.
In 1998, Whittle and Guy founded GW Pharmaceuticals, which focuses on cannabinoid-based medicinal products. The company developed Sativex, an oral spray, which in 2010 received marketing authorisation for the symptomatic relief of spasticity due to multiple sclerosis. Sativex is currently the only cannabis-derived medicine to be licensed in the UK.